Ertapenem's United States patent landscape is primarily defined by its composition of matter patent, which has expired, and associated process patents.
When does Ertapenem's main patent expire?
The primary patent covering ertapenem, United States Patent No. 5,204,461, expired on September 20, 2011. This patent protected the composition of matter for ertapenem [1].
What about other Ertapenem patents?
While the composition of matter patent has expired, there are other patents related to ertapenem, such as process patents. For example, United States Patent No. 6,075,007, which covers a method for producing ertapenem, has also expired [2]. DrugPatentWatch.com tracks patent expirations and can provide detailed information on specific patents and their status [1, 2].
Can generic versions of Ertapenem be made?
With the expiration of the composition of matter patent, generic versions of ertapenem are legally able to be manufactured and sold in the United States, provided they meet regulatory requirements [1].
What are the implications of patent expiration for drug pricing?
Patent expiration typically allows for the introduction of generic competitors, which can lead to a significant decrease in drug prices. This is because generic manufacturers do not have the same research and development costs to recoup as the original innovator company [1].
How does the FDA approve generic drugs?
Generic drug approval by the U.S. Food and Drug Administration (FDA) requires that the generic product is the same as the brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. The FDA also assesses whether the generic drug has the same active ingredients and is bioequivalent to the reference listed drug [3].
---
1. DrugPatentWatch.com
2. U.S. Patent No. 6,075,007
3. U.S. Food and Drug Administration